Enzalutamide capsule

DRUG4 trials

Sponsors

Astellas Pharma Europe B.V., National Cancer Institute (NCI), CHU de Quebec-Universite Laval, Fundacion Oncosur

Conditions

Metastatic Prostate CancerPharmacokinetics of EnzalutamideProstate Cancer

Phase 1

Relative Bioavailability Study of Enzalutamide in Prostate Cancer Patients

CompletedNCT01902251

Astellas Pharma Europe B.V.Pharmacokinetics of Enzalutamide, Prostate Cancer

Start: 2012-11-30End: 2013-10-31Updated: 2014-09-09

Study to Compare Capsule and Liquid Formulations of Enzalutamide After Single Dose Administration Under Fasting Conditions in Prostate Cancer

TerminatedNCT03478904

National Cancer Institute (NCI)Prostate Cancer

Start: 2020-03-10End: 2020-11-30Updated: 2021-05-10

Phase 2

Detecting Metastases by PyL PET/CT in Subjects Starting Enzalutamide for Untreated Castration Resistant Prostate Cancer.

Active, not recruitingNCT04655365

CHU de Quebec-Universite LavalProstate Cancer

Start: 2022-03-22End: 2026-09-01Target: 50Updated: 2025-12-23

Talazoparib Plus Enzalutamide After Progression to Abiraterone in Metastatic Prostate Cancer: (TEAM PC)

RecruitingNCT06582628

Fundacion OncosurMetastatic Prostate Cancer

Start: 2024-07-05End: 2027-10-31Target: 78Updated: 2024-12-02

Related Papers

Safety of continued administration of enzalutamide in patients with prostate cancer who showed benefit from prior exposure: A phase 2 open-label extension study.

Journal of Clinical Oncology2018-02-201 citations